{"name":"Myriad Genetics","slug":"myriad","ticker":"MYGN","exchange":"NASDAQ","domain":"myriad.com","description":"Myriad Genetics, Inc. is an American genetic testing and precision medicine company based in Salt Lake City, Utah, United States. Myriad employs a number of proprietary technologies that permit doctors and patients to understand the genetic basis of human disease and the role that genes play in the onset, progression and treatment of disease. This information is used to guide the development of new products that assess an individual's risk for developing disease later in life, identify a patient's likelihood of responding to a particular drug therapy, assess a patient's risk of disease progression and disease recurrence, and measure disease activity.","hq":"Salt Lake City, UT","founded":0,"employees":"2700","ceo":"Paul J. Diaz","sector":"Molecular Diagnostics / Precision Medicine","stockPrice":3.69,"stockChange":-0.04,"stockChangePercent":-1.07,"marketCap":"$348M","metrics":{"revenue":771400000,"revenueGrowth":-20.8,"grossMargin":68.1,"rdSpend":106800000,"netIncome":-365900000,"cash":149600000,"dividendYield":0,"peRatio":22.2,"fiscalYear":"FY2017"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2023-08-03","type":"earnings","headline":"Myriad Genetics Reports Second Quarter 2023 Financial Results","summary":"Myriad Genetics reported revenue of $143.4 million for the second quarter of 2023, a decrease of 2% compared to the same period in 2022.","drugName":"","sentiment":"neutral"},{"date":"2023-06-01","type":"deal","headline":"Myriad Genetics Announces Collaboration with Invitae to Develop and Commercialize Genetic Tests","summary":"Myriad Genetics has entered into a collaboration with Invitae to develop and commercialize genetic tests for hereditary cancer and other diseases.","drugName":"","sentiment":"positive"},{"date":"2022-08-04","type":"earnings","headline":"Myriad Genetics Reports Second Quarter 2022 Financial Results","summary":"Myriad Genetics reported revenue of $146.2 million for the second quarter of 2022, an increase of 5% compared to the same period in 2021.","drugName":"","sentiment":"neutral"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi5AFBVV95cUxQaWU4akxwTnZRTzdDa3RTY1A2VVpnTk5jNWFhSU5FY0tiajN0YmNmSEpQdlpfVnc0WXd0dktjR19FVzZrSXBkVGVRdmRoUDYtcGdZS1ZJV2lCNDdTRjBTS3NJVHBCVXNORnBvak9zMGROaVFrS1JHa0JQU3NHRlV5Y1RZOU5VdWQxTzRzMWpCelBzUkdmQmI2OGF2MVh2MEhtM1d3OVEtTVVrZUFxcW1WMlR4Mk1oaUNBOG1fejdDVk15NzBVYzJaS2h2R0JiM0tZV05admdRbGlXOUUxbTEzckZCMDU?oc=5","date":"2026-04-06","type":"earnings","source":"TradingView","summary":"Q4 Earnings Highlights: Myriad Genetics (NASDAQ:MYGN) Vs The Rest Of The Therapeutics Stocks - TradingView","headline":"Q4 Earnings Highlights: Myriad Genetics (NASDAQ:MYGN) Vs The Rest Of The Therapeutics Stocks","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihgJBVV95cUxPb1BLTHY2ZGVhV2ZweE5aTENualJKOUJGRWVia0owMVZwSnd0S0x2RE1PSzNvTGxHNTk3bks0aWs3XzB5ZUN4YWJJbG1fYXZEUlE0dVh2c19RR2d4aERsOW9tbzV5TzNON1FhbUoxcUdMS1ZCY3ZSb0FubkNzendjNWEzY3ZlWlNubDR1QklKSHo1ek1JbTZ0RkZ5V21aWnBrTDlmOWNET1VIb2FwaXZ0UGFvZWtWR1ZqQTJKRGlNWTlPS0JxUzlraUNnVmZHUjhrblFZMGdwOUVZbVB5NVp1RXlPY0NXUDlCOUloZ205bW5OQ1V2VHJUMURVZTNuTGhGUXRuUHln?oc=5","date":"2026-04-06","type":"earnings","source":"The Globe and Mail","summary":"Q4 Earnings Highlights: Myriad Genetics (NASDAQ:MYGN) Vs The Rest Of The Therapeutics Stocks - The Globe and Mail","headline":"Q4 Earnings Highlights: Myriad Genetics (NASDAQ:MYGN) Vs The Rest Of The Therapeutics Stocks","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihgFBVV95cUxPTGxoVUFSbVMwQTlfQUxra1VQLXZoT1JPTFFhd3ZkaWp3QlM5THd1VWlkU0wtX3R1UXdYdFZwZldYbWhtc3RXM1JnMm5sTkQwWURmVUJpX3J3NUNMbHdObUVDazdqdUphNW1DeFhoXzdnMnBtQ2ZVamdvQl9mcjFCWnIxalA1UQ?oc=5","date":"2026-03-11","type":"pipeline","source":"Yahoo Finance","summary":"Stocks making big moves yesterday: nLIGHT, Myriad Genetics, Vertex Pharmaceuticals, Nextpower, and Teladoc - Yahoo Finance","headline":"Stocks making big moves yesterday: nLIGHT, Myriad Genetics, Vertex Pharmaceuticals, Nextpower, and Teladoc","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-02-13","type":"earnings","source":"simplywall.st","summary":"Little Excitement Around Myriad Genetics, Inc.'s (NASDAQ:MYGN) Revenues As Shares Take 27% Pounding - simplywall.st","headline":"Little Excitement Around Myriad Genetics, Inc.'s (NASDAQ:MYGN) Revenues As Shares Take 27% Pounding","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-02-04","type":"pipeline","source":"simplywall.st","summary":"Does Myriad Genetics (NASDAQ:MYGN) Have A Healthy Balance Sheet? - simplywall.st","headline":"Does Myriad Genetics (NASDAQ:MYGN) Have A Healthy Balance Sheet?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi5AFBVV95cUxNTlo0U2xKT2VTRVNkLTUzZUhGa3k0Ql9YX3l2MHQ2ZlV1SUo2a0pCaEJjUlVhcXFseEdXdng5R0F4TzViMXRwaE9IcFdpc0NTR1hCdDRQczFGSTJFQ3RpcmNXTFdpNmtiWmV5ZkpQdEVibTdabTdaRHJoMUNPMVlEWEYxN080M1lfQXcxc25CU1lMZ0V1cTFmU3E1WFV6MVVWMkg3ZnZRd29ud2JBNjJzdnZOckJ1Sl9kOVF1ZnlzWUJySjF5STIxbkxOUWptY18yYkV6WjJVU21KX2NTbnFRcjJ5REE?oc=5","date":"2026-01-21","type":"pipeline","source":"The Globe and Mail","summary":"2 Healthcare Stocks with Solid Fundamentals and 1 That Underwhelm - The Globe and Mail","headline":"2 Healthcare Stocks with Solid Fundamentals and 1 That Underwhelm","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi4AFBVV95cUxNY0hNWmlkVG9sZWp4OUlQUDJ6blh6VUF0NHY0NnpvOGZ0Tkc4RmRTblZralVHY19id2RBSkM2T1c4bElhS1d3VVplbm9DQkw5RnVReDBiUG5ua0VmNmtIbkdlNjZ3eXg4Ni00RGVHc0dsTkM5R294TFJXaFk1cXlHMTdqcWliQlQyZDc4TXpYZzBrOVFQaF9SdnhtNXJYZl9rSW9GRFhWSEEtbGtoY3IwdG4xTGZRdUlUVndQMmIyM3JVWDJEQ1NTUGdFUXEzOC0zaXlmOVFXQ0JsdGZLMHBRdg?oc=5","date":"2025-11-11","type":"pipeline","source":"TradingView","summary":"Merck, Elanco, Myriad Genetics, Neogen, and Cigna Shares Are Soaring, What You Need To Know - TradingView","headline":"Merck, Elanco, Myriad Genetics, Neogen, and Cigna Shares Are Soaring, What You Need To Know","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi9gFBVV95cUxOM0d4Znhtc0RNTHZpRDZmMncyV19Td1BFd3JmQTRmS0F2LVUycExxa0daUjI5emJpN2ZpaGhGQ2pqenJwdkpNdDlLdEt6b0dEcnBSZXBjNmRMVEFqZDREczhRQlBaSmFnSS1xckM5NWJ3bks3YUtYMTd1amd1MEJQSEJVLTVsZTF2TTI5T0ZXc0lkTG50TFVMdTJ1VE5GVXNEMVFVYXFRUldwY2N1aFg1YnRtejBYNWVaSVZYQXZ1VWJzeVp0MkN1WTJkT3RjLVh0WGdDUDhOMEpXZDYxcjJlUXpmMF9GcmRpTzBrdmNJUWZRckpoQ2c?oc=5","date":"2025-09-23","type":"pipeline","source":"PR Newswire","summary":"Myriad Genetics and SOPHiA GENETICS to Develop an Innovative Companion Diagnostic Offering in Liquid Biopsy - PR Newswire","headline":"Myriad Genetics and SOPHiA GENETICS to Develop an Innovative Companion Diagnostic Offering in Liquid Biopsy","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi3wFBVV95cUxPQ0xVa1pHOXlpV3ZmS0hYODRTT3h2RUdVLS1xU0hOd0hvQkVBanB6R1pFcnVpOFoyZ0QtakxPel9HeEF5d2VjdDZYNFRpQ3RvYTE2eUlSSXRPb0NDa21hTWJkSnpWRTQ2YjZZdk9HWlk4MVBPM2pQaDZJaWtDSm11UkNxNGRxc1k3ZVhmazhybXVPSXRMSXRwbDczS0VDYmpJeHh4QzRfWnpUek03NkxCU29lck1FRHFScklDd3Z3bmdoaDlObmYyTGk0azN1RXQwX3pCclQ3dW5JQkNMbGxz?oc=5","date":"2025-07-15","type":"earnings","source":"StockStory","summary":"Q1 Earnings Roundup: Gilead Sciences (NASDAQ:GILD) And The Rest Of The Therapeutics Segment - StockStory","headline":"Q1 Earnings Roundup: Gilead Sciences (NASDAQ:GILD) And The Rest Of The Therapeutics Segment","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMizAFBVV95cUxPazlYRHJfNEg1UURKa1hVSC1RTGRnZlpQWEFUU1g2V2pzZzRuTElnQ295MXRBdm5IT1dra3dSY3ZhSVRTOEM1ZWJjcUpPV3YzZGkwbnZ2LXdqR2Jna3E5RmM3Z3phSTR0TUsyQk9vSkxFQTRCSTJ1bF9tbEI4dEh6Y2hnaFdDelNwUzdYOUJxMkk3T3NlVFNNQ3d4RFlSRkw5Y2FoUnJVYnN6S0tnTUpPbm8xQ1RzS19CYlQ5TVpPQzF5REc4YzhyV0xURG4?oc=5","date":"2025-05-26","type":"earnings","source":"StockStory","summary":"Spotting Winners: Myriad Genetics (NASDAQ:MYGN) And Therapeutics Stocks In Q1 - StockStory","headline":"Spotting Winners: Myriad Genetics (NASDAQ:MYGN) And Therapeutics Stocks In Q1","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitwFBVV95cUxQTU9XUzFEZ3NIT1Z5cmw5bVpoTXY5ZUE0dTctY19IWWxaT1EzeDBjaTBTMVE1a2F5a29PY2ZrUWpzLWlGY21FSFRHVVJmUFFiTGFfLWthR2dLZFlzdFdHV1RtQnhnWk1ocVJRc1FMMTJFT3diRzV3bVBQeGdVVDU0S1Y0YS01aWJOLWNISlNiMVpsRUNzaVpNR252OTM2QS0yRk51Qkgtb1RGZ2ZrUno5dU1sV1JGX1U?oc=5","date":"2021-05-25","type":"earnings","source":"Mintz","summary":"Mintz Advises Myriad Genetics in Sale of Pharmaceutical Research Services Business, Myriad RBM, to Q2 Solutions - Mintz","headline":"Mintz Advises Myriad Genetics in Sale of Pharmaceutical Research Services Business, Myriad RBM, to Q2 Solutions","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi_wFBVV95cUxNSWQ1SFltNWdWd2U2MVF3VkJLS2dQZVZfLUxUXy1Ec19OSzQ3U0NIQmJfeGZBYUdxQVZHUDV6cmVScVZ3RFkxMmdpcnZFU1dObEpDa3B2NllTWnBUWWFlX1BzY0JjeTFjUG9wWEx3MUk1SDRuQS1ETFJsVm1jb2NfTWtDWE1kTGx1QllZTkJtdWdVZWQ2U3JNb3ZNazBTdVVpQ0lMb1BUZmJVQVBZazlfWFNhZUFRYXlQRzlIUHQzc0w4MG1pNWxoTnF2TkdxazlPdzdINnFkSkdHalM0aHZXblpUUVo1ZmhVQzQxZ3FqZk5xcGxqbFhBN3JOa2x6V00?oc=5","date":"2019-07-19","type":"deal","source":"Dark Daily","summary":"Kroger Prescription Plans Partners with Myriad Genetics to Offer GeneSight Genetic Tests and Genetic Counseling in Kroger Pharmacies - Dark Daily","headline":"Kroger Prescription Plans Partners with Myriad Genetics to Offer GeneSight Genetic Tests and Genetic Counseling in Kroge","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Invitae","Foundation Medicine","Exact Sciences"],"therapeuticFocus":["Oncology","Genetic Testing"],"financials":{"source":"sec_edgar+yahoo","revenue":771400000,"revenuePeriod":"2017-06-30","revenueHistory":[{"value":771400000,"period":"2017-06-30"},{"value":753800000,"period":"2016-06-30"},{"value":723100000,"period":"2015-06-30"},{"value":778216000,"period":"2014-06-30"},{"value":613165000,"period":"2013-06-30"},{"value":496005000,"period":"2012-06-30"}],"grossProfit":576600000,"grossProfitHistory":[{"period":"2025-12-31","value":576600000},{"period":"2024-12-31","value":585400000},{"period":"2023-12-31","value":517000000},{"period":"2022-12-31","value":476400000}],"rdSpend":106800000,"rdSpendHistory":[{"period":"2025-12-31","value":106800000},{"period":"2024-12-31","value":113400000},{"period":"2023-12-31","value":88700000},{"period":"2022-12-31","value":85400000}],"sgaSpend":537600000,"operatingIncome":-67800000,"operatingIncomeHistory":[{"period":"2025-12-31","value":-67800000},{"period":"2024-12-31","value":-88000000},{"period":"2023-12-31","value":-144600000},{"period":"2022-12-31","value":-123700000}],"netIncome":-365900000,"netIncomeHistory":[{"period":"2025-12-31","value":-365900000},{"period":"2024-12-31","value":-127300000},{"period":"2023-12-31","value":-263300000},{"period":"2022-12-31","value":-112000000}],"eps":-3.95,"epsHistory":[{"period":"2025-12-31","value":-3.95},{"period":"2024-12-31","value":-1.41},{"period":"2023-12-31","value":-3.18},{"period":"2022-12-31","value":-1.39}],"cash":149600000,"cashHistory":[{"period":"2025-12-31","value":149600000},{"period":"2024-12-31","value":102400000},{"period":"2023-12-31","value":132100000},{"period":"2022-12-31","value":56900000}],"totalAssets":706600000,"totalLiabilities":338600000,"totalDebt":209800000,"equity":368000000,"operatingCashflow":1800000,"operatingCashflowHistory":[{"period":"2025-12-31","value":1800000},{"period":"2024-12-31","value":-8700000},{"period":"2023-12-31","value":-110900000},{"period":"2022-12-31","value":-106300000}],"capex":-27400000,"capexHistory":[{"period":"2025-12-31","value":-27400000},{"period":"2024-12-31","value":-29700000},{"period":"2023-12-31","value":-73300000},{"period":"2022-12-31","value":-45300000}],"freeCashflow":-25600000,"dividendsPaid":null,"buybacks":0,"employees":2700,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[{"sga":135800000,"ebit":-30000000,"ebitda":-17500000,"period":"2026-03-31","revenue":200400000,"epsBasic":-0.36,"netIncome":-34100000,"rdExpense":27100000,"epsDiluted":-0.36,"grossProfit":137600000,"operatingIncome":-25300000},{"sga":124300000,"ebit":-4500000,"ebitda":8100000,"period":"2025-12-31","revenue":209800000,"epsBasic":-0.08,"netIncome":-7900000,"rdExpense":25500000,"epsDiluted":-0.08,"grossProfit":146800000,"operatingIncome":-3000000},{"sga":138900000,"ebit":-22400000,"ebitda":-9800000,"period":"2025-09-30","revenue":205700000,"epsBasic":-0.29,"netIncome":-27400000,"rdExpense":28200000,"epsDiluted":-0.29,"grossProfit":143800000,"operatingIncome":-23300000},{"sga":138700000,"ebit":-329100000,"ebitda":-315000000,"period":"2025-06-30","revenue":213100000,"epsBasic":-3.57,"netIncome":-330500000,"rdExpense":25600000,"epsDiluted":-3.57,"grossProfit":151800000,"operatingIncome":-12500000},{"sga":135700000,"ebit":-28600000,"ebitda":-14200000,"period":"2025-03-31","revenue":195900000,"epsBasic":0,"netIncome":-100000,"rdExpense":27500000,"epsDiluted":0,"grossProfit":134200000,"operatingIncome":-29000000},{"sga":null,"ebit":null,"ebitda":null,"period":"2024-12-31","revenue":null,"epsBasic":null,"netIncome":null,"rdExpense":null,"epsDiluted":null,"grossProfit":null,"operatingIncome":null}]},"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":3.69,"previousClose":3.73,"fiftyTwoWeekHigh":8.59,"fiftyTwoWeekLow":3.64,"fiftyTwoWeekRange":"3.64 - 8.59","fiftyDayAverage":4.71,"twoHundredDayAverage":6.03,"beta":1.64,"enterpriseValue":201591824,"forwardPE":22.2,"priceToBook":1.03,"priceToSales":0.62,"enterpriseToRevenue":0.36,"enterpriseToEbitda":-1.8,"pegRatio":0,"ebitda":-111900000,"ebitdaMargin":-20.1,"freeCashflow":-46062500,"operatingCashflow":-26200000,"totalDebt":0,"debtToEquity":32.8,"currentRatio":2.67,"returnOnAssets":-7.6,"returnOnEquity":-23.5,"analystRating":"3.0 - Hold","recommendationKey":"hold","numberOfAnalysts":8,"targetMeanPrice":6.25,"targetHighPrice":10,"targetLowPrice":4,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":3.3,"institutionHeldPercent":94,"sharesOutstanding":94448210,"floatShares":85994151,"sharesShort":7883496,"shortRatio":7.7,"shortPercentOfFloat":8.4,"epsTrailing":-4.31,"epsForward":0.17,"revenuePerShare":7.45,"bookValue":3.57,"officers":[{"age":52,"name":"Mr. Samraat S. Raha","title":"President, CEO & Director"},{"age":41,"name":"Mr. Benjamin R. Wheeler","title":"CFO & Principal Accounting Officer"},{"age":57,"name":"Mr. Mark S. Verratti","title":"Chief Operating Officer"},{"age":45,"name":"Dr. Dale  Muzzey Ph.D.","title":"Chief Scientific Officer"},{"age":63,"name":"Mr. Paul J. Diaz J.D.","title":"Consultant"},{"age":42,"name":"Mr. Brian  Donnelly","title":"Chief Commercial Officer"},{"age":null,"name":"Mr. Matthew  Scalo","title":"Senior Vice President of Investor Relations"},{"age":52,"name":"Ms. Jennifer L. Fox J.D.","title":"Chief Legal Officer"}],"industry":"Diagnostics & Research","irWebsite":"http://investor.myriad.com/","website":"https://www.myriad.com","phone":"801 584 3600"}}